ArticleJAAD case reports2020
Bullous pemphigoid secondary to pembrolizumab mimicking toxic epidermal necrolysis.
Article in JAAD case reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Immune checkpoint inhibitor-induced bullous pemphigoid: a systematic review of clinical characteristics and outcomes based on case reports.Frontiers in immunology · 2026Pooled it
- Steroid resistant bullous pemphigoid induced by pembrolizumab in a patient with metastatic lung adenocarcinoma: case report and review of the literature.Discover oncology · 2025Article
- An Adverse Double-Hit by Pembrolizumab: A Case Report of Bullous Pemphigoid and Pneumonitis.Journal of medical cases · 2025Article
- Immune checkpoint inhibitor-induced epidermal necrolysis: A narrative review evaluating demographics, clinical features, and culprit medications.The Journal of dermatology · 2024Review
- Article
- Analysis of the clinical characteristics of pembrolizumab-induced bullous pemphigoid.Frontiers in oncology · 2023Article
- Pembrolizumab-induced Toxic Epidermal Necrolysis in a Patient with Metastatic Esophageal Adenocarcinoma.Rhode Island medical journal (2013) · 2022Article
- Bullous Pemphigoid in Patients Receiving Immune-Checkpoint Inhibitors and Psoriatic Patients-Focus on Clinical and Histopathological Variation.Dermatopathology (Basel, Switzerland) · 2022Article
- Skin Manifestation Induced by Immune Checkpoint Inhibitors.Clinical, cosmetic and investigational dermatology · 2022Review
- An Unusual TEN-Like Presentation of Juvenile Bullous Pemphigoid: A Diagnostic Challenge.Case reports in dermatological medicine · 2022Article
- Strategies to Improve Outcomes of Bullous Pemphigoid: A Comprehensive Review of Clinical Presentations, Diagnosis, and Patients' Assessment.Clinical, cosmetic and investigational dermatology · 2022Review
- A Rare Case of Bullous Pemphigoid Secondary to Checkpoint Inhibitor Immunotherapy: A Tense Situation.Cureus · 2021Article
- Bullous pemphigoid mimicking toxic epidermal necrolysis.Anais brasileiros de dermatologiaArticle
- Refractory Bullous Pemphigoid in a Patient with Metastatic Lung Adenocarcinoma Treated with Pembrolizumab.Case reports in oncologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.